BioMed X have entered into a collaboration agreement with Boehringer Ingelheim to establish a research group focusing on the identification of novel therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD).
|Searching for more deal information? Current Partnering offers the following options:
BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility, providing entrepreneurial education and enabling access to the Heidelberg scientific community and research facilities.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends